MEDICINES FOR CANCER TREATMENT

To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KAWAKAMI YUTAKA, MATSUI AYUKO, KATO HIROTAKA, YAGUCHI TOMONORI, SHOJI TORU, WAKUI TSUGUNORI
Format: Patent
Sprache:eng ; jpn
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is used with concomitant administration of an immune checkpoint inhibitor according to the following regimen (a) and (b) to maintain the anti-tumor activity of the T cells: (a) an effective amount of the T cells is administered to a cancer patient; and (b) the immune checkpoint inhibitor is continuously administered in an amount of 0.01-100 mg/kg body weight every 1-5 week.SELECTED DRAWING: None 【課題】GPC1陽性のがんを効果的に治療する医薬組成物、キット及び技術を提供する。【解決手段】グリピカン1(GPC1)に結合するキメラ抗原受容体を有するT細胞を有効成分とし、下記(a)及び(b)のレジメンで免疫チェックポイント阻害剤と共に投与することにより前記T細胞の抗腫瘍活性を維持するための、がん治療用医薬。(a)がん患者に前記T細胞の有効量を投与する(b)前記がん患者に1回あたり0.01mg/kg体重〜100mg/kg体重の前記免疫チェックポイント阻害剤を、1〜5週間ごとに継続投与する【選択図】なし